The combined use of apixaban and inducers of CYP3A4 and/or P-gp was associated with an increased risk of venous thromboembolism (HR 1.58; 1.0–2.5) (Fig. 4 and Fig 5). The gene discussed is PGP; the disease is venous thromboembolism.